Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Review
PubMed
28886236
DOI
10.1111/ejh.12959
Knihovny.cz E-resources
- Keywords
- B-Lymphocytes, Clone Cells, Immunophenotyping, Waldenstrom Macroglobulinemia,
- MeSH
- B-Lymphocytes metabolism pathology MeSH
- Phenotype MeSH
- Genetic Heterogeneity MeSH
- Genetic Variation MeSH
- Immunophenotyping MeSH
- Clonal Evolution genetics MeSH
- Humans MeSH
- Plasma Cells metabolism pathology MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Signal Transduction MeSH
- Tumor Burden MeSH
- Waldenstrom Macroglobulinemia diagnosis etiology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Waldenström's macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell-derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long-lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B-cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B-lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B- and plasma cell tumor WM clones.
Department of Biology and Ecology Faculty of Science University of Ostrava Ostrava Czech Republic
Department of Clinical Haematology University Hospital Brno Brno Czech Republic
Department of Clinical Studies Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Haemato Oncology University Hospital Ostrava Ostrava Czech Republic
References provided by Crossref.org